The antiproliferative cytostatic effects of a self-activating viridin prodrug

Molecular Cancer Therapeutics

Volumn 8, Issue 6, 2009, Pages 1666-1675

  Smith, Adam ^a   Blois, Joseph ^a   Yuan, Hushan ^a   Aikawa, Elena ^a   Ellson, Christian ^c   Figueiredo, Jose Luiz ^a   Weissleder, Ralph ^b   Kohler, Rainer ^a   Yaffe, Michael B ^c   Cantley, Lewis C ^b   Josephson, Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; PACLITAXEL; PRODRUG; SELF ACTIVATING VIRIDIN; UNCLASSIFIED DRUG; VINBLASTINE; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; CYTOSTASIS; DRUG ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY BURST; TUMOR XENOGRAFT;

ANDROSTENES; ANIMALS; BACTERIOCINS; BLOOD VESSELS; CARBOCYANINES; CELL LINE; CELL PROLIFERATION; CYTOSTATIC AGENTS; EAR; FLOW CYTOMETRY; HALF-LIFE; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; PERITONEUM; PRODRUGS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649386846     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1012     Document Type: Article

References (25)

1. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436 (Pubitemid 38745528)
2. Wipf P, Halter Robert J. Chemistry and biology of wortmannin. Org Biomol Chem 2005;3:2053-2061 (Pubitemid 40859876)
3. Hanson JR. The viridin family of steroidal antibiotics. Nat Prod Rep 1995;12:381-384
4. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996; 16:1722-1733 (Pubitemid 26095645)
5. Yuan H, Barnes KR, Weissleder R, Cantley L, Josephson L. Covalent reactions of wortmannin under physiological conditions. Chem Biol 2007; 14:321-328 (Pubitemid 46428147)
6. Norman BH, Shih C, Toth JE, et al. Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs. J Med Chem 1996;39:1106-1111 (Pubitemid 26082943)
7. Creemer LC, Kirst HA, Vlahos CJ, Schultz RM. Synthesis and in vitro evaluation of new wortmannin esters: potent inhibitors of phosphatidylinositol 3-kinase. J Med Chem 1996;39:5021-5024 (Pubitemid 26422519)
8. Schultz RM, Merriman RL, Andis SL, et al. In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res 1995;15:1135-1139
9. Blois J, Yuan H, Smith A, et al. Slow self-activation enhances the potency of viridin prodrugs. J Med Chem 2008;51:4699-4707
10. Yuan H, Luo J, Weissleder R, Cantley L, Josephson L. Wortmannin- C20 conjugates generate wortmannin. J Med Chem 2006;49:740-747
11. Kratz F, Muller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem 2008;3:20-53.
12. Barnes KR, Blois J, Smith A, et al. Fate of a bioactive fluorescent wortmannin derivative in cells. Bioconjug Chem 2008;19:130-137 (Pubitemid 351213843)
13. Darzynkiewicz Z, Juan G, Bedner E. Current protocols in cell biology. New York: John Wiley & Sons; 1999.
14. Ellson CD, Davidson K, Ferguson GJ, O'Connor R, Stephens LR, Hawkins PT. Neutrophils from p40phox./. mice exhibit severe defects in NADPHoxidas e regulation and oxidant-dependent bacterial killing. J Exp Med 2006;203:1927-1937 (Pubitemid 44188467)
15. Zask A, Kaplan J, Toral-Barza L, et al. Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy. J Med Chem 2008;51:1319-1323
16. Ihle NT, Williams R, Chow S, et al. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3- kinase signaling. Mol Cancer Ther 2004;3:763-772 (Pubitemid 39193758)
17. Powis G, Ihle N, Kirkpatrick DL. Practicalities of drugging the phosphatidylinositol- 3-kinase/Akt cell survival signaling pathway. Clin Cancer Res 2006;12:2964-2966 (Pubitemid 43837339)
18. Baggiolini M, Dewald B, Schnyder J, Ruch W, Cooper PH, Payne TG. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. Exp Cell Res 1987;169: 408-418 (Pubitemid 17056606)
19. Arcaro A, Wymann MP. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-triphosphate in neutrophil responses. Biochem J 1993;296:297-301.
20. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 2006;125:733-747
21. Ruckle T, Schwarz MK, Rommel C. PI3Kγ inhibition: towards an 'aspirin of the 21st century'? Nat Rev Drug Discov 2006;5:903-918
22. Kaneo Y, Uemura T, Tanaka T, Kanoh S. Polysaccharides as drug carriers: biodisposition of fluorescein-labeled dextrans in mice. Biol Pharm Bull 1997;20:181-187 (Pubitemid 27123170)
23. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98:335-344 (Pubitemid 43338213)
24. 2-M delay. Clin Cancer Res 1997;3: 1149-1156
25. Oikawa T, Shimamura M. Potent inhibition of angiogenesis by wortmannin, a fungal metabolite. Eur J Pharmacol 1996;318:93-96 (Pubitemid 27033209)